Sinopharm Falls on $515 Million Share-Sale Plan: Hong Kong Mover

Sinopharm Group Co. (1099), China’s biggest drug distributor, posted the largest decline in almost three years in Hong Kong trading after saying it will sell as much as HK$4 billion ($515 million) in new shares.

Sinopharm fell 7.2 percent to HK$25.05 at the close in Hong Kong, the largest drop since May 25, 2010. The stock was the fourth-biggest decliner on the MSCI Asia Pacific excluding Japan Index.

The company will sell as many as 165.7 million shares to between six and 10 non-retail investors at HK$24.60 each to raise money for expanding its sales network, Shanghai-based Sinopharm said in a filing today. That’s 8.9 percent less than the stock’s closing price yesterday. The number of shares is equivalent to 16.67 percent and 6.45 percent, respectively, of Sinopharm’s enlarged H-share and total issued share capital after the sale, it said.

“The company needed the money to continue growing,” Carol Xiao, a Shanghai-based analyst at UOB Kay Hian Investment Co. said today. Sinopharm will probably sell additional shares after this year to fund growth, she said.

Sinopharm said it will use the funds raised “for the expansion of pharmaceutical distribution and retail network and replenishment of liquidity after the expansion.”

Photographer: Doug Kanter/Boomberg

A cyclist rides past the Sinopharm Group Co. headquarters in Beijing. Close

A cyclist rides past the Sinopharm Group Co. headquarters in Beijing.

Close
Open
Photographer: Doug Kanter/Boomberg

A cyclist rides past the Sinopharm Group Co. headquarters in Beijing.

State-owned China National Pharmaceutical Group Corp. will retain control of the company after the sale, according to the statement.

Morgan Stanley, UBS AG and China International Capital Corp. are the placing agents for the sale.

To contact the reporter on this story: Benjamin Haas in Hong Kong at bhaas7@bloomberg.net

To contact the editor responsible for this story: Jason Rogers at jrogers73@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.